Analyzing mitotic chromosome structural defects after topoisomerase II inhibition or mutation

Juan F. Giménez-Abián; Andrew B. Lane; Duncan J. Clarke

doi:10.1007/978-1-4939-7459-7_15

Analyzing mitotic chromosome structural defects after topoisomerase II inhibition or mutation

Juan F. Giménez-Abián, Andrew B. Lane, Duncan J. Clarke

Genetics, Cell Biology and Development (TMED)

Research output: Chapter in Book/Report/Conference proceeding › Chapter

4 Scopus citations

Abstract

For analyzing chromosome structural defects that result from topoisomerase II (topo II) dysfunction we have adapted classical cell cycle experiments, classical cytological techniques and the use of a potent topo II inhibitor (ICRF-193). In this chapter, we describe in detail the protocols used and we discuss the rational for our choice and for the adaptations applied. We clarify in which cell cycle stages each of the different chromosomal aberrations induced by inhibiting topo II takes place: lack of chromosome segregation, undercondensation, lack of sister chromatid resolution, and lack of chromosome individualization. We also put these observations into the context of the two topo II-dependent cell cycle checkpoints. In addition, we have devised a system to analyze phenotypes that result when topo II is mutated in human cells. This serves as an alternative strategy to the use of topo II inhibitors to perturb topo II function.

Original language	English (US)
Title of host publication	Methods in Molecular Biology
Publisher	Humana Press Inc.
Pages	191-215
Number of pages	25
DOIs	https://doi.org/10.1007/978-1-4939-7459-7_15
State	Published - 2018

Publication series

Name	Methods in Molecular Biology
Volume	1703
ISSN (Print)	1064-3745

Bibliographical note

Funding Information:
The chromosome preparation technique was originally devised in Prof. Robert T Johnson’s laboratory (Mammalian Cell DNA Repair Group, University of Cambridge, UK) and has been modified over the years by Drs. Giménez-Abián and Clarke. Silver impregnation was developed for mammalian mitotic chromosomes by Dr. Giménez-Abián, but is based on methods used to stain meiotic grasshopper chromosomes by Rufas et al. [10, 11]. HeLa EM2-11ht cells were provided by Weiderfeld et al. [8]. Development of the protocols described in this chapter was partly dependent on funding from grants BFU2008-03579/BMC and 2008201165 from the VICT (MCI, Spain) and NIH grant CA099033 to DJC.

Publisher Copyright:
© 2018, Springer Science+Business Media, LLC.

Keywords

Chromatid resolution
Chromosome individualization
Condensation
ICRF-193
Topo II checkpoint
Topoisomerase II

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1007/978-1-4939-7459-7_15

OpenUrl availability

Full text

Cite this

@inbook{60536b473c994ddd853631b13f9190a2,

title = "Analyzing mitotic chromosome structural defects after topoisomerase II inhibition or mutation",

abstract = "For analyzing chromosome structural defects that result from topoisomerase II (topo II) dysfunction we have adapted classical cell cycle experiments, classical cytological techniques and the use of a potent topo II inhibitor (ICRF-193). In this chapter, we describe in detail the protocols used and we discuss the rational for our choice and for the adaptations applied. We clarify in which cell cycle stages each of the different chromosomal aberrations induced by inhibiting topo II takes place: lack of chromosome segregation, undercondensation, lack of sister chromatid resolution, and lack of chromosome individualization. We also put these observations into the context of the two topo II-dependent cell cycle checkpoints. In addition, we have devised a system to analyze phenotypes that result when topo II is mutated in human cells. This serves as an alternative strategy to the use of topo II inhibitors to perturb topo II function.",

keywords = "Chromatid resolution, Chromosome individualization, Condensation, ICRF-193, Topo II checkpoint, Topoisomerase II",

author = "Gim{\'e}nez-Abi{\'a}n, {Juan F.} and Lane, {Andrew B.} and Clarke, {Duncan J.}",

note = "Funding Information: The chromosome preparation technique was originally devised in Prof. Robert T Johnson{\textquoteright}s laboratory (Mammalian Cell DNA Repair Group, University of Cambridge, UK) and has been modified over the years by Drs. Gim{\'e}nez-Abi{\'a}n and Clarke. Silver impregnation was developed for mammalian mitotic chromosomes by Dr. Gim{\'e}nez-Abi{\'a}n, but is based on methods used to stain meiotic grasshopper chromosomes by Rufas et al. [10, 11]. HeLa EM2-11ht cells were provided by Weiderfeld et al. [8]. Development of the protocols described in this chapter was partly dependent on funding from grants BFU2008-03579/BMC and 2008201165 from the VICT (MCI, Spain) and NIH grant CA099033 to DJC. Publisher Copyright: {\textcopyright} 2018, Springer Science+Business Media, LLC.",

year = "2018",

doi = "10.1007/978-1-4939-7459-7_15",

language = "English (US)",

series = "Methods in Molecular Biology",

publisher = "Humana Press Inc.",

pages = "191--215",

booktitle = "Methods in Molecular Biology",

}

TY - CHAP

T1 - Analyzing mitotic chromosome structural defects after topoisomerase II inhibition or mutation

AU - Giménez-Abián, Juan F.

AU - Lane, Andrew B.

AU - Clarke, Duncan J.

N1 - Funding Information: The chromosome preparation technique was originally devised in Prof. Robert T Johnson’s laboratory (Mammalian Cell DNA Repair Group, University of Cambridge, UK) and has been modified over the years by Drs. Giménez-Abián and Clarke. Silver impregnation was developed for mammalian mitotic chromosomes by Dr. Giménez-Abián, but is based on methods used to stain meiotic grasshopper chromosomes by Rufas et al. [10, 11]. HeLa EM2-11ht cells were provided by Weiderfeld et al. [8]. Development of the protocols described in this chapter was partly dependent on funding from grants BFU2008-03579/BMC and 2008201165 from the VICT (MCI, Spain) and NIH grant CA099033 to DJC. Publisher Copyright: © 2018, Springer Science+Business Media, LLC.

PY - 2018

Y1 - 2018

N2 - For analyzing chromosome structural defects that result from topoisomerase II (topo II) dysfunction we have adapted classical cell cycle experiments, classical cytological techniques and the use of a potent topo II inhibitor (ICRF-193). In this chapter, we describe in detail the protocols used and we discuss the rational for our choice and for the adaptations applied. We clarify in which cell cycle stages each of the different chromosomal aberrations induced by inhibiting topo II takes place: lack of chromosome segregation, undercondensation, lack of sister chromatid resolution, and lack of chromosome individualization. We also put these observations into the context of the two topo II-dependent cell cycle checkpoints. In addition, we have devised a system to analyze phenotypes that result when topo II is mutated in human cells. This serves as an alternative strategy to the use of topo II inhibitors to perturb topo II function.

AB - For analyzing chromosome structural defects that result from topoisomerase II (topo II) dysfunction we have adapted classical cell cycle experiments, classical cytological techniques and the use of a potent topo II inhibitor (ICRF-193). In this chapter, we describe in detail the protocols used and we discuss the rational for our choice and for the adaptations applied. We clarify in which cell cycle stages each of the different chromosomal aberrations induced by inhibiting topo II takes place: lack of chromosome segregation, undercondensation, lack of sister chromatid resolution, and lack of chromosome individualization. We also put these observations into the context of the two topo II-dependent cell cycle checkpoints. In addition, we have devised a system to analyze phenotypes that result when topo II is mutated in human cells. This serves as an alternative strategy to the use of topo II inhibitors to perturb topo II function.

KW - Chromatid resolution

KW - Chromosome individualization

KW - Condensation

KW - ICRF-193

KW - Topo II checkpoint

KW - Topoisomerase II

UR - http://www.scopus.com/inward/record.url?scp=85035103531&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85035103531&partnerID=8YFLogxK

U2 - 10.1007/978-1-4939-7459-7_15

DO - 10.1007/978-1-4939-7459-7_15

M3 - Chapter

C2 - 29177744

AN - SCOPUS:85035103531

T3 - Methods in Molecular Biology

SP - 191

EP - 215

BT - Methods in Molecular Biology

PB - Humana Press Inc.

ER -

Analyzing mitotic chromosome structural defects after topoisomerase II inhibition or mutation

Abstract

Publication series

Bibliographical note

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this